ReviewCNS drugs2015
[(18)F]Florbetaben: a review in β-amyloid PET imaging in cognitive impairment.
Review in CNS drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring.Molecular diagnosis & therapy · 2026Review
- Comparison of plasma p-tau217 and p-tau181 in predicting amyloid positivity and prognosis among Korean memory clinic patients.Scientific reports · 2025Article
- Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Radiolabeled Probes from Derivatives of Natural Compounds Used in Nuclear Medicine.Molecules (Basel, Switzerland) · 2024Review
- Sensitivity of unconstrained quantitative magnetization transfer MRI to Amyloid burden in preclinical Alzheimer's disease.medRxiv : the preprint server for health sciences · 2024Article
- Sensitivity of unconstrained quantitative magnetization transfer MRI to amyloid burden in preclinical Alzheimer's disease.Imaging neuroscience (Cambridge, Mass.) · 2024Article
- Comparing Neurofilament Light Chain Levels in Serum and Plasma.Dementia and neurocognitive disorders · 2023Article
- Patterns of Focal Amyloid Deposition UsingDiagnostics (Basel, Switzerland) · 2022Article
- The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.Scientific reports · 2021Article
- Single and Combined Neuroimaging Techniques for Alzheimer's Disease Detection.Computational intelligence and neuroscience · 2021Review
- Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia.International journal of molecular sciences · 2020Review
- Divergence in the metabolome between natural aging and Alzheimer's disease.Scientific reports · 2020Article
- 3D-Deep Learning Based Automatic Diagnosis of Alzheimer's Disease with Joint MMSE Prediction Using Resting-State fMRI.Neuroinformatics · 2020Article
- CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment.Alzheimer's & dementia (New York, N. Y.) · 2020Review
- Whole Brain Voxel-Wise Analysis of Cerebral Retention of Beta-Amyloid in Cognitively Normal Older Adults UsingPsychiatry investigation · 2017Article
- Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Imaging Alzheimer's disease pathophysiology with PET.Dementia & neuropsychologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous (18)F-labelled florbetaben ([(18)F]florbetaben) [Neuraceq™] is a polyethylene glycol stilbene derivative that is approved in the USA, EU and South Korea for positron emission tomography (PET) imaging of the brain. It is used to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. In vitro, [(18)F]florbetaben has high affinity and selectivity for β-amyloid. It has a short PET scan time (15-20 min). Visual assessment of regional and whole brain [(18)F]florbetaben PET images detected brain β-amyloid with high sensitivity and specificity, with good inter-reader agreement, in a phase III study in patients with various levels of cognitive function when compared with postmortem histopathological assessment. The whole brain visual assessment displayed high positive and negative predictive values, enabling amyloid pathology to be reliably detected or excluded. Quantitative PET analyses were generally consistent with the visual assessments. [(18)F]florbetaben was generally well tolerated in clinical trials. All adverse reactions in [(18)F]florbetaben recipients were mild to moderate in severity and the most common were injection-site-related (erythema, irritation and pain). There were no serious adverse reactions related to [(18)F]florbetaben. In summary, [(18)F]florbetaben is a highly accurate β-amyloid PET tracer that has the potential to support the clinical diagnosis of Alzheimer's disease and other causes of cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.